Ignite Creation Date:
2024-05-06 @ 9:19 AM
Last Modification Date:
2024-10-26 @ 12:12 PM
Study NCT ID:
NCT02950064
Status:
UNKNOWN
Last Update Posted:
2019-01-14
First Post:
2016-10-05
Brief Title:
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
Sponsor:
Placon Therapeutics
Organization:
Placon Therapeutics
Study Overview
Official Title:
Escalation Study of BTP-114 in Patients With Advanced Solid Tumors and BRCA or DNA Repair Mutation
Status:
UNKNOWN
Status Verified Date:
2019-01
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase 1 Open-label multicenter Dose Escalation study of BTP-114 a novel platinum product in patients with advanced solid tumors and BRCA or other DNA repair mutation This clinical study is comprised of 2 sequential parts Part 1 Dose Escalation and Part 2 Expansion The purpose of this study is to evaluate the safety pharmacokinetics and the anti-cancer activity of BTP-114
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None